GENSCRIPT BIO (01548): Meng Jiangge appointed as a director of Legend Biotech

22:13 23/01/2026

Kingstray Biotechnology (01548) announced that, starting from January 20, 2026, Legendary Biotechnology Limited ("Legendary"), a joint venture of the company and listed on the Nasdaq Global Select Market in the form of American Depositary Shares, has appointed Mr. Meng Jiange as a director, with an initial term until the annual shareholders' meeting of Legendary in 2026. Mr. Meng Jiange has been appointed to replace Dr. Zhu Li on the board of Legendary, who resigned from the position on the effective date.

GENSCRIPT BIO (01548) announces that Legend Biotech Corporation ("Legend"), a joint venture company of the company, whose shares are listed on the NASDAQ Global Select Market in the form of American depositary shares, has appointed Mr. Meng Jiange as a director of the board, with an initial term until the annual shareholder meeting of Legend in 2026. Mr. Meng Jiange has been appointed to replace Dr. Zhu Li on the board of Legend, effective from the date of appointment. Dr. Zhu Li has resigned from the position.

Real estate profits continue to shrink, with multiple real estate companies issuing profit warning announcements for 2025.

TCL Zhonghuan Renewable Energy Technology's subsidiary plans to sell 100% equity of SPMY.

US Stock Market Move | Most concept stocks of lithium mines have risen, Sigma Lithium (SGML.US) up more than 15%.

Real estate profits continue to shrink, with multiple real estate companies issuing profit warning announcements for 2025.

TCL Zhonghuan Renewable Energy Technology's subsidiary plans to sell 100% equity of SPMY.

US Stock Market Move | Most concept stocks of lithium mines have risen, Sigma Lithium (SGML.US) up more than 15%.